Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
Conclusion Combination of quinacrine and erlotinib was well tolerated but showed limited efficacy in advanced NSCLC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva | Toxicology